index — Zealand pharma

22-06-2017 Dasiglucagon effective in Phase 2a trial in the iLet™ dual-hormone pump platform for treatment of type 1 diabetes READ MORE

22-06-2017
Dasiglucagon effective in Phase
2a trial in the iLet™ dual-hormone
pump platform for treatment of
type 1 diabetes

19-06-2017 Glepaglutide meets primary endpoint in Phase 2 trial in patients with short bowel syndrome Read more

19-06-2017
Glepaglutide meets primary
endpoint in Phase 2 trial in patients
with short bowel syndrome

We are a Danish biotech company discovering and developing novel peptide-based medicines. We are passionate about improving patients’ lives and committed to delivering value for all our stakeholders. We intend to be a world leader in medicines focusing on specialty gastrointestinal and metabolic diseases. SEE VIDEO ABOUT ZEALAND

We are a Danish biotech company discovering and developing novel peptide-based medicines. We are passionate about improving patients’ lives and committed to delivering value for all our stakeholders. We intend to be a world leader in medicines focusing on specialty gastrointestinal and metabolic diseases.

SEE VIDEO ABOUT ZEALAND

22-06-2017 Dasiglucagon effective in Phase 2a trial in the iLet™ dual-hormone pump platform for treatment of type 1 diabetes READ MORE

19-06-2017 Glepaglutide meets primary endpoint in Phase 2 trial in patients with short bowel syndrome Read more

We are a Danish biotech company discovering and developing novel peptide-based medicines. We are passionate about improving patients’ lives and committed to delivering value for all our stakeholders. We intend to be a world leader in medicines focusing on specialty gastrointestinal and metabolic diseases. SEE VIDEO ABOUT ZEALAND

Subscribe to news

Subscribe and keep up to date with Zealand Pharma A/S news. Read more

Product pipeline

View our pipeline and pre-clinical partnered programs. Read more

Dual-hormone pump

Learn more about the iLet™ from our partner Beta Bionics. See the video

Meet 3 SBS patients

Learn more about Short Bowel Syndrome (SBS) from three Danish patients. View video

Upcoming events

Featured

November 14-15, 2018

Jefferies Healthcare Conference, London

December 12-13, 2018

Nordea Healthcare trip to Zealand, Glostrup

See all events
See financial calendar

News

Share price

Our research

Applying our peptide platform to specialty disease areas to invent novel therapies.
Read more

2 marketed products

Branded products in diabetes care commercialized by Sanofi under a worldwide license. Read more

Our Company

Get a brief overview on Zealand Pharma A/S and learn more about our Company.
Read more

Shareholder portal

As a shareholder, you can access a wide range of investor information.
Read more

Understanding the impact of
acute, severe hypoglycemia

Read about the ready-to-use dasiglucagon hypo pen

Every day is a struggle to live a "normal" life with SBS

Read about our product candidate targeting short bowel disease

Annual Report 2016

Annual Report 2016 and video with CEO Britt Meelby Jensen.